Focused On-demand Library for Ribonuclease T2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O00584

UPID:

RNT2_HUMAN

Alternative names:

Ribonuclease 6

Alternative UPACC:

O00584; B2RDA7; E1P5C3; Q5T8Q0; Q8TCU2; Q9BZ46; Q9BZ47

Background:

Ribonuclease T2, alternatively known as Ribonuclease 6, plays a pivotal role in innate immune response by degrading RNAs from microbial pathogens, which are then recognized by TLR8. This enzyme preferentially cleaves single-stranded RNA between purine and uridine residues, facilitating the generation of purine-2',3'-cyclophosphate-terminated oligoribonucleotides. These degradation products are essential for the RNA-dependent activation of TLR8. Additionally, Ribonuclease T2 is involved in the degradation of mitochondrial RNA and the processing of non-coding RNA within mitochondria, as well as the degradation of mitochondrion-associated cytosolic rRNAs.

Therapeutic significance:

Ribonuclease T2 is implicated in Leukoencephalopathy, cystic, without megalencephaly, a syndrome characterized by cerebral leukoencephalopathy, microcephaly, and neurologic abnormalities. Understanding the role of Ribonuclease T2 could open doors to potential therapeutic strategies for this condition.